Epitalon Oral Bioavailability: What the Research Shows

Epitalon's oral bioavailability is generally considered very low — likely in the low single digits or less — because this four-amino-acid peptide is broken down by stomach acid and intestinal enzymes before it can reach the bloodstream. No peer-reviewed human study has ever published an exact oral bioavailability figure for Epitalon. Because of that, subcutaneous injection and intranasal delivery remain the routes used in almost all published research.

That gap between marketing claims and published data is the heart of the issue. Here is what is actually known about oral epitalon, what is only assumed, and what remains unmeasured.

What Is Epitalon?

Epitalon — also spelled Epithalon and known as AEDG — is a synthetic tetrapeptide made from four amino acids: alanine, glutamic acid, aspartic acid, and glycine. It was developed in Russia by Vladimir Khavinson and colleagues, who studied it for effects on telomerase activity, pineal gland function, and circadian rhythm.

Most of the human data comes from small, older Russian studies that used subcutaneous injections or intranasal drops. Epitalon is not FDA-approved for human use in the United States, and it is legally sold as a research chemical rather than a dietary supplement.

Why Peptides Have Poor Oral Bioavailability

The digestive tract is built to break peptides into single amino acids, which works against any peptide taken by mouth. Four barriers matter most.

• Enzymatic degradation: pepsin in the stomach and trypsin, chymotrypsin, and brush-border peptidases in the small intestine cleave peptide bonds before absorption happens.
• Poor membrane permeability: Epitalon is small but hydrophilic, so it crosses the lipid-rich intestinal wall inefficiently.
• First-pass metabolism: whatever is absorbed travels through the portal vein to the liver, where it can be broken down again.
• Acid instability: low gastric pH degrades unprotected peptides before they ever reach the intestine.

These barriers are why nearly every peptide therapeutic on the market is injected. The only oral peptide drug approved in the United States, oral semaglutide, uses a specialized absorption enhancer called SNAC and still reaches roughly 1% bioavailability.

Is There Any Measured Oral Bioavailability Data for Epitalon?

No. No human pharmacokinetic study reports Cmax, AUC, or absolute bioavailability for oral Epitalon in the peer-reviewed literature.

What exists instead is Russian-language research using injection and intranasal routes, plus a small number of animal studies on the AEDG peptide. That evidence base does not answer the oral question.

Vendor pages that advertise "high oral bioavailability" for Epitalon capsules are making a marketing claim, not reporting a measured result. Published reviews of peptide drug delivery consistently report that unmodified peptides absorb at rates below 1% to 2% unless a specialized carrier is used.

How the Routes Compare

Injection places the peptide directly into systemic circulation, so the dose on the label is roughly the dose the body receives. Oral dosing has to survive the gut first, and that loss is unpredictable from person to person.

Oral Epitalon, CJC-1295, and Other Peptides Sold in Capsules

Epitalon is not the only peptide marketed in pill or liquid form, and the same delivery problem applies to nearly every compound in that category.

Anyone comparing a cjc-1295 oral supplement with injectable CJC-1295 is facing the same issue: a 30-amino-acid peptide has even less chance than a tetrapeptide of surviving the gut intact. The same logic applies to a cjc 1295 ipamorelin oral troche, where absorption depends on the molecule passing through the thin tissue under the tongue instead of the intestinal wall.

Mucosal routes can help, but they do not remove the size and solubility limits. Comparisons of kpv peptide oral vs injection run into the same constraints. Small molecules behave differently: discussions of slu-pp-332 oral vs injection often note that a compound of that size and lipophilicity crosses the gut wall far more efficiently than any tetrapeptide.

The practical takeaway is that route of administration changes everything for peptides, and an oral capsule is usually the least efficient option available.

Safety and Legal Status

Epitalon is not FDA-approved for human use, and no regulatory agency verifies the purity, identity, or dose of products sold as research chemicals. Because no human oral pharmacokinetic study exists, there is no established safe oral dose.

Anyone considering a peptide for a health purpose should speak with a licensed healthcare professional first. Laboratory researchers should follow their institution's handling and documentation requirements.